Global collaboration to innovate more natural and additive-free nutraceuticals12 Apr 2019
Initiative will enable Sirio Pharma to keep abreast of regional trends, new ingredients, dosage forms and claims to provide customers unique product ideas for line extensions.
Nutraceutical CDMO Sirio Pharma has announced a global collaboration to help customers bring innovative, safe and effective products quickly to market.
With access to the most recent market data, Sirio’s 100+ scientists and industry experts, based in Asia, Europe and the US, will combine research and development efforts to focus on proactive innovation. By combining its expertise, Sirio is now even better positioned to work with customers worldwide.
“The industry demands products that are more natural and additive free, with consumer-friendly labeling and increased transparency. The challenge for brand owners is how to develop these products quickly without compromising on quality. Our global collaboration will be instrumental in helping our customers develop innovative products that conform with these trends. It’s a big challenge for companies to improve existing formulations – it requires a large and experienced in-house R&D team. With over 500 stock formulas, our R&D specialists will explore novel combinations of ingredients, ensuring products are effective, shelf stable and great tasting,” commented Rui Yang, CSO of Sirio Pharma.
The global collaboration will enable Sirio to keep abreast of regional trends, new ingredients, dosage forms and claims to provide customers unique product ideas for line extensions. Another key objective is to provide customers with more clean label options for their products such as natural flavors, colors and sweeteners and eco-friendly packaging solutions. Ultimately, Sirio seeks to empower customers from all markets to advance product R&D more rapidly and confidently launch new products faster. Great examples of this new collaborative effort at work include new products such as Curcumin Gummies and Probiotic and Collagen Supplements.
“This collaboration is the natural evolution of our commitment to continuous improvement and forward thinking. The key in this industry is speed to market – being able to rapidly bring new products from concept to commercialization. We take an extremely proactive approach to our new product development pipeline, planning up to three years in advance as to where consumer preferences are heading” added Rui Yang, CSO of Sirio Pharma.
Sirio has a long history of developing new approaches and proactively innovating. The company successfully launched a premium nutra consumer brand in China, Treerly Health, which was acquired by Pfizer in 2016.
Exploristics surges ahead with £1m investment
14 Apr 2019
The loan will be used to develop KERUS Cloud - currently the only software that can simulate trials with multiple correlated outcomes - by integrating it into an intelligent software ecosystem.Read more
Isotype-specific secondary antibodies for improved signal detection
10 Apr 2019
Offer an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.Read more
Sterling Pharma to acquire CiVentiChem in the US
9 Apr 2019
The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.Read more
New China-based biotechs fueling growth in manufacturing across China
9 Apr 2019
New guidelines will see poorer quality manufacturers drop out of the market.Read more
TTP spin-out to commercialise next-generation cell-sorting technology
7 Apr 2019
Highway 1 addresses a major unmet need for improved cell-sorting technology, with applications including development of cell therapies, liquid biopsy diagnostics, and high-throughput drug discovery.Read more
Catalent expands OptiMelt hot melt extrusion capabilities
4 Apr 2019
The investment includes the addition of equipment to enhance development capabilities for preclinical and early clinical phase development, as well as adding downstream processing technologies to support HME formulations.Read more
'Drugs from bugs' joint venture
4 Apr 2019
Lonza and Chr. Hansen create a strategic joint venture to become the partner of choice for developing and manufacturing live biotherapeutic products for pharma and biotech customers.Read more
BASF launches three new active ingredients derived from the rambutan tree
2 Apr 2019
The ingredients are extracted from the first organically certified rambutan gardens in Vietnam.Read more
Sartorius integrates online biomass measurement to its ambr systems for microbial applications
1 Apr 2019
Scientists to rapidly obtain detailed process understanding and control over their microbial cultures.Read more
Cambrex doubles cGMP liquid filling capacity at its Mirabel facility
1 Apr 2019
Investment will improve production cycle time and provide greater flexibility to customers.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation